Company news
Galectin Therapeutics Inc. (NASDAQ:GALT) news
Galectin Therapeutics Inc. news releases on 6ix. Latest, Sep 2, 2020: Galectin Therapeutics Appoints Joel Lewis as Chief Executive Officer
Press releases — page 3
Galectin Therapeutics Appoints Joel Lewis as Chief Executive Officer
September 1, 2020
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2020, and Provides Business Update
August 9, 2020
Galectin Therapeutics Announces Commencement of Patient Enrollment of the Adaptively-Designed Phase 2b/3 Trial of Belapectin in NASH Cirrhosis
June 29, 2020
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2020, and Provides Business Update
May 10, 2020
Galectin Therapeutics Submits Seamless Adaptively-Designed Phase 2b/3 NASH-RX Protocol in NASH Cirrhosis
April 29, 2020
Galectin Therapeutics Update on the Impact of COVID-19
April 1, 2020
Galectin Therapeutics Reports Fiscal 2019 Financial Results and Provides Business Update
March 15, 2020
Galectin Therapeutics Appoints Seasoned Biopharmaceutical Executive Pol F. Boudes, M.D. as Chief Medical Officer
February 19, 2020
Galectin Therapeutics’ Phase 2 NASH Cirrhosis Clinical Trial Results on Belapectin (GR-MD-02) Published in Gastroenterology
December 8, 2019
Galectin Therapeutics Plans Adaptively Designed Phase 3 NASH-RX Clinical Trial in NASH Cirrhosis
December 4, 2019
Galectin Therapeutics Reports Q3 2019 Financial Results
November 11, 2019
Galectin Therapeutics Reaches Agreement with Siemens Healthineers to Collaborate on NASH and Liver Fibrosis
November 10, 2019
Galectin Therapeutics, Inc. and Providence Cancer Institute Receive Patent on the Use of Belapectin (GR-MD-02) in Cancer Immunotherapy
September 16, 2019
Galectin Therapeutics Inc. Announces Record Date, Subscription Pricing, and Expiration Date for Rights Offering and Effectiveness of its Registration Statement
April 14, 2019